A new top drug regulator and the future of psychedelics
On this week’s episode of “The Readout Loud”: a look at an emerging class of psychedelic drugs that may treat depression, anxiety, and other psychiatric conditions without the hallucinogenic “trip.” Plus, a dash through the week’s biotech news.
The turmoil at the Food and Drug Administration continues: Richard Pazdur has announced his retirement from the agency, just a month after taking the job as top drug regulator. He’s being replaced by Covid contrarian Tracy Beth Høeg. We also discuss a U.K.-U.S pharma trade agreement, a very large financing round for an AI-tinged longevity startup, and a big Phase 3 study win for Capricor Therapeutics and its Duchenne muscular dystrophy cell therapy.
Elaine Chen, Adam Feuerstein, and Allison DeAngelis
Go to statnews